Secalciferol是一种来源于植物和真菌的脂溶性维生素（(24R)-24,25-Dihydroxyvitamin D3），可激活维生素D受体（VDR；EC50=150nM）。
Cas No.:55721-11-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Secalciferol is a fat-soluble vitamin derived from plants and fungi, also known as (24R)-24,25-Dihydroxyvitamin D3. Secalciferol activates the vitamin D receptor (VDR) with an EC50 of 150nM[1-2]. Secalciferol is involved in various biological functions, including calcium homeostasis, cell differentiation, proliferation processes, and other functions related to the immune system. Secalciferol can be used in research on rickets, osteomalacia, hypercalcemia, and autoimmune diseases[3-4].
In vitro, Secalciferol (100pM - 10μM) was used to treat the IZ-VDRE and IZ-CYP24 stably transfected reporter gene cell lines for 24 hours. Secalciferol demonstrated a dose-dependent activation of the vitamin D receptor (VDR). The half-maximal effective concentration (EC50) of Secalciferol in the IZ-VDRE and IZ-CYP24 cell lines was 140.8nM and 166.1nM[5]. In the chondrogenic ATDC5 cell differentiation model, treatment with Secalciferol (0.1μM) for 7-14 days enhanced the gene expression of type 2 collagen (Col2a1) in Tlcd3b2-overexpressing cells, promoted proteoglycan synthesis, and facilitated the early differentiation of chondrocytes[6].
In vivo, Cyp24a1 knockout (Cyp24a1-/-) mice in a fracture repair model received subcutaneous injections of Secalciferol (6.7μg/kg/day) for 15 days. Secalciferol significantly corrected the defects in callus formation and callus stiffness during fracture repair in Cyp24a1-/- mice, restored callus volume, and improved the mechanical properties of the callus[7]. In hypophosphatemic (Hyp) mice, daily intraperitoneal injections of Secalciferol (1-1000μg/kg/day) for 28 days. Secalciferol significantly promoted bone formation in the lumbar vertebrae and improved bone formation parameters such as bone volume/tissue volume ratio and mineral apposition rate in a dose-dependent manner[8].
References:
[1] Henderson CM, Fink SL, Bassyouni H, et al. Vitamin D-Binding Protein Deficiency and Homozygous Deletion of the GC Gene. The New England Journal of Medicine. 2019 Mar;380(12):1150-1157.
[2] Wilson RT, Roff AN, Dai PJ, et al. Genetic Ancestry, Skin Reflectance and Pigmentation Genotypes in Association with Serum Vitamin D Metabolite Balance. Hormone Molecular Biology and Clinical Investigation. 2011 Sep;7(1):279-293.
[3] Makris K, Bhattoa HP, Cavalier E, et al. Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein - A position paper from the IFCC Committee on bone metabolism. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2021 Jun;517:171-197.
[4] Ikezaki S, Nishikawa A, Furukawa F, et al. Influences of long-term administration of 24R, 25-dihydroxyvitamin D3, a vitamin D3 derivative, in rats. J Toxicol Sci. 1999 May;24(2):133-9.
[5] Bartonkova I, Grycova A, Dvorak Z. Profiling of Vitamin D Metabolic Intermediates toward VDR Using Novel Stable Gene Reporter Cell Lines IZ-VDRE and IZ-CYP24. Chem Res Toxicol. 2016 Jul 18;29(7):1211-22.
[6] Antonyan L, Martineau C, St-Arnaud R. The ER protein TLC domain 3B2 and its enzymatic product lactosylceramide enhance chondrocyte maturation. Connect Tissue Res. 2021 Mar;62(2):176-182.
[7] Martineau C, Naja RP, Husseini A, et al. Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2. J Clin Invest. 2018 Aug 1;128(8):3546-3557.
[8] Ono T, Tanaka H, Yamate T, et al. 24R,25-dihydroxyvitamin D3 promotes bone formation without causing excessive resorption in hypophosphatemic mice. Endocrinology. 1996 Jun;137(6):2633-7.
Secalciferol是一种来源于植物和真菌的脂溶性维生素（(24R)-24,25-Dihydroxyvitamin D3），可激活维生素D受体（VDR；EC50=150nM）[1-2]。Secalciferol参与多种生物功能，包括钙的平衡，细胞分化和增殖过程以及与免疫系统相关的其他功能，可用于对佝偻病，软骨症，高钙血症和自身免疫性疾病的研究[3-4]。
在体外，Secalciferol（100pM-10μM）处理IZ-VDRE和IZ-CYP24两种稳定转染的报告基因细胞系24小时。Secalciferol能够剂量依赖性地激活维生素D受体（VDR）。Secalciferol在IZ-VDRE和IZ-CYP24细胞系中的半数最大效应浓度（EC50）分别为140.8nM和166.1nM[5]。Secalciferol（0.1μM）处理软骨源性ATDC5细胞分化模型7-14天。Secalciferol能够增强Tlcd3b2过表达细胞中2型胶原（Col2a1）的基因表达，并促进蛋白多糖的合成和软骨细胞的早期分化[6]。
在体内，Secalciferol（6.7μg/kg/day；持续15天）进行皮下注射治疗Cyp24a1基因敲除（Cyp24a1-/-）小鼠骨折修复模型。Secalciferol显著纠正了Cyp24a1-/-小鼠在骨折修复过程中骨痂形成和骨痂刚度的缺陷，恢复了骨痂体积并提高了骨痂的机械性能[7]。给低磷酸盐血症（Hyp）小鼠每日腹腔注射Secalciferol（1-1000μg/kg/day），持续28天。Secalciferol显著促进了腰椎的骨骼形成，并以剂量依赖性方式改善了骨形成参数（如骨体积/组织体积比、矿物沉积率）[8]。
| Cell experiment [1]: | |
Cell lines | ATDC5 cells (mouse chondrogenic teratocarcinoma cell line) |
Preparation Method | The ATDC5 prechondrogenic cells were cultured in DMEM/F12 medium supplemented with 5% FBS. For differentiation, ATDC5 cells were cultured in DMEM/F12 medium supplemented with Insulin-Transferrin-Sodium Selenite (ITS). Where indicated, cells were treated with Secalciferol (0.1μM) in charcoal-stripped FBS. |
Reaction Conditions | 0.1μM; 14 day. |
Applications | In ATDC5 cells overexpressing Tlcd3b2, treatment with 0.1μM Secalciferol significantly increased the gene expression of the early chondrogenic differentiation marker Col2a1 compared to untreated cells. |
| Animal experiment [2]: | |
Animal models | Hypophosphatemic (Hyp) mice (a model for X-linked hypophosphatemic rickets) and normal control mice. |
Preparation Method | The mice were divided into groups and received daily intraperitoneal injections for 28 days. Hyp mice received either Secalciferol at doses of 1-1000μg/kg/day. Control mice received no treatment or vehicle. |
Dosage form | 1-1000μg/kg/day; i.p.; Daily for 28 days. |
Applications | Treatment of Hyp mice with Secalciferol dose-dependently promoted bone formation in the fifth lumbar (L5) vertebrae, as evidenced by increased parameters such as the length of the L5 spine, mineral apposition rate (MAR), and mineralized bone volume/bone volume (Md.BV/BV). |
References: | |
| Cas No. | 55721-11-4 | SDF | |
| 别名 | 司骨化醇; (24R)-24,25-Dihydroxyvitamin D3 | ||
| Canonical SMILES | C=C(CC1)/C(C[C@H]1O)=C\C=C2[C@@]3([H])[C@@](CCC\2)(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)(C)O)CC3 | ||
| 分子式 | C27H44O3 | 分子量 | 416.64 |
| 溶解度 | DMSO : 100 mg/mL (240.02 mM; Need ultrasonic); Ethanol : 50 mg/mL (120.01 mM; Need ultrasonic) | 储存条件 | Store at -20°C, protect from light, stored under nitrogen,unstable in solution, ready to use. |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL |
| 5 mM | 480 μL | 2.4002 mL | 4.8003 mL |
| 10 mM | 240 μL | 1.2001 mL | 2.4002 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet